Abstract:BACKGROUND: Sufficient dose of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen may be an ideal treatment option for renal transplant recipients, and the regimen has been widely used in clinic due to its low nephrotoxicity, few adverse reactions and strong immunosuppressive effects. OBJECTIVE: To investigate the efficacy and safety of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid regimen in renal transplantation patients with the control of mycophenolate mofetil combined with standard-dose tacrolimus and corticosteroid. METHODS: A total of 210 patients receiving a single-organ renal al ograft were randomly divided into standard-dose tacrolimus group (n=104) and low-dose tacrolimus group (n=106). Individual patients were treated for 12 months. The primary efficacy endpoints were the chronic al ograft damage index and glomerular filtration rate at 12 months after transplantation. The secondary efficacy end points mainly included the acute rejection rate, treatment failure rate, and the survival rate of patient and transplant kidney. The safety parameters such as new onset of post-transplantation diabetes mel itus, hypertension and hyperlipidemia were also evaluated. RESULTS AND CONCLUSION: The vast majorities of patients were administrated with sufficient dose of mycophenolate mofetil (1.5 g/d or above) in two groups. The majority of the patients in standard-dose tacrolimus group had the mean trough level below the protocol-defined, which led to the similar mean trough level between standard-dose and low-dose tacrolimus group. These could also confirm that the regimen of mycophenolate mofetil combined with low-dose tacrolimus and corticosteroid had been wildly accepted and used by clinicians. The efficacy and safety of two groups were similar. The mean chronic al ograft damage index of the renal pathological changes at 12 months after transplantation in standard-dose and low-dose tacrolimus group were 1.82 and 2.13 respectively (P=0.081 3), the mean glomerular filtration rates were 77.08 mL/min and 80.12 mL/min (P=0.794 9), acute rejection rates were 2.6% and 5.2% (P=0.681 2), and the survival rates of patients and transplant kidney were 100% and 99.1% (P=1.000 0). The rates of new onset of post-transplantation diabetes mel itus in the standard-dose and low-dose tacrolimus group were 2.9% and 1.9%, and the rates of hyperlipidemia were 2.9% and 3.8%, respectively. For the regimen of mycophenolate mofetil combined with tacrolimus and corticosteroid, the utilization of sufficient dose of mycophenolate mofetil could reduce the dose of tacrolimus, thereby significantly reducing the nephrotoxicity, hyperlipidemia and new onset of post-transplantation diabetes mel itus caused by tacrolimus and achieving a good balance of efficacy and toxicity when maintaining a strong immune inhibition and reducing the acute rejection incidence successful y.

The Effect of Tacrolimus on Carbohydrate Metabolism and Controlling

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Retrospective study on curative effect of tacrolimus used in renal transplant recipients

Effects of conversion from tacrolimus to cyclosporine A therapy on new-onset diabetes mellitus after kidney transplantation

The Tacrolimus-Induced Glucose Homeostasis Imbalance in Terms of the Liver: from Bench to Bedside

Advances in the study of post-transplantation diabetes mellitus resulting from tacrolimus via calcineurin/NFAT signaling

Application of Tacrolimus in 862 Renal Transplantation Recipients

Effects of Tacrolimus on Insulin Receptors in Rat Hepatocytic Membrane

Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients

Long-term curative effect of tacrolimus in kidney transplantation patients in China:Meta-analysis

Effects of Steroids-Free Immunosuppressive Treatment for Membranous Nephropathy Combining with Type 2 Diabetes Mellitus

Effect of cytochrome P450 3A5 (CYP3A5) genotype on tacrolimus dose requirement in renal transplant patients

Clinical study of tacrolimus in postoperative treatment of patients with renal transplantation for diabetic end-stage renal disease]

Anti-acute Rejection Regime with Tacrolimus in Renal Transplantation Patients

Effect of Low-Dose Tacrolimus with Mycophenolate Mofetil on Renal Function Following Liver Transplantation.

Comparison of the efficacy of low-dosage versus standard-dosage tacrolimus after kidney transplantation by programming renal biopsies

Long-term beneficial effect of tacrolimus conversion on renal transplant recipients

Higher Tacrolimus Blood Concentration is Related to Increased Risk of Post-Transplantation Diabetes Mellitus after Living Donor Liver Transplantation

Conversion from Cyclosporine to Tacrolimus in Patients with Chronic Allograft Nephropathy

Effect of CYP3A5 Genotype on Concentration and Efficacy of Tacrolimus in Patients with Kidney Transplantation

Clinical comparison of tacrolimus and CsA in end stage renal disease of diabetic renal allograft recipients